Directed share issue in Oncopeptides AB (SE) — SEK 1,106 million

Carnegie acted as joint bookrunner in the directed share issue of 7,000,000 shares at a subscription price of SEK 158 per share. Oncopeptides is a global biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases and was recently granted accelerated approval by the U.S. Food and Drug Administration for PEPAXTO (melphalan flufenamide, also known as melflufen) in relapsed or refractory multiple myeloma.
March 2021.